Enterprise Financial Services Corp Nektar Therapeutics Transaction History

Enterprise Financial Services Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 04, 2020	SELL	$16.86 - $23.44 $809 - $1,125	-48 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $694 - $1,342	48 New	48 $1,000
Q3 2019 Oct 31, 2019	SELL	$16.91 - $36.27 $33,820 - $72,540	-2,000 Closed	0 $0
Q1 2019 Apr 26, 2019	BUY	$31.58 - $46.35 $63,160 - $92,700	2,000 New	2,000 $67,000
Q4 2018 Jan 25, 2019	SELL	$30.43 - $56.65 $699 - $1,302	-23 Closed	0 $0
Q3 2018 Oct 26, 2018	BUY	$46.46 - $68.49 $1,068 - $1,575	23 New	23 $1,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $146M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Enterprise Financial Services Corp, based on Form 13F filings with the SEC.

Stay updated on Enterprise Financial Services Corp with notifications on news.